Source: Eur Respir J 2013; 41: 1393-1400
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Vija Skripconoka, Manfred Danilovits, Lea Pehme, Tarmo Tomson, Girts Skenders, Tiina Kummik, Andra Cirule, Vaira Leimane, Anu Kurve, Klavdia Levina, Lawrence J. Geiter, Davide Manissero, Charles D. Wells. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400

Member's Comments

No comment yet.

Related content which might interest you: Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Predictors of treatment outcome in multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis Source: Eur Respir J 2009; 34: 180-183 Year: 2009 Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction Source: Eur Respir Rev 2009; 18: 295-299 Year: 2009 Pulmonary tuberculosis with primary drug resistant mycobacterium tuberculosis -treatment outcomes Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal Source: Eur Respir J 2013; 42: 1747-1749 Year: 2013 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Long-term results of multidrug-resistant tuberculosis treatment. Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Management and treatment of multidrug-resistant tuberculosis Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Effect of fluoroquinolones on microbiologic outcome and survival in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 380s Year: 2006 The WHO strategy for TB control and elimination Source: Eur Respir Mon 2012; 58: 242-253 Year: 2012 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007